CNS pipelines merged as Biotie buys Newron
This article was originally published in Scrip
The Finnish biotech firm Biotie Therapies is to acquire the Italian company Newron Pharmaceuticals in an all-share deal valuing the latter at €45 million and the combined group at around €195 million. The merger brings together two CNS pipelines with each company contributing a late-stage product with an existing pharma partner.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.